Invirsa is developing INV-102, a topical eye drop derived from a naturally occurring small molecule that modulates DNA damage repair pathways including p53 and Pax6. INV-102 has completed initial testing in dry eye patients (Phases 1 and 2a) and has shown reduced cellular injury/death in vitro and superior efficacy in several animal models. The company plans a Phase 2 clinical program including studies in acute infectious keratoconjunctivitis (Q3 2023), a Phase 2 pilot in Fuchs Endothelial Corneal Dystrophy (Q4 2023), and an additional dry eye study (Q1 2024), with funds earmarked for Phase 3 preparation. Invirsa’s projects have received federal support, including funding from BARDA and other Department of Health and Human Services programs. The management team includes experienced drug developers and ophthalmology advisors focused on reducing signs and symptoms of dry eye and other ocular surface conditions. Invirsa is an Ohio pharmaceutical company focused on enhancing the body’s natural defenses to protect against and treat infectious diseases. Its lead candidate, INV-102, is derived from a naturally occurring small molecule and works by strengthening the innate immune response and stimulating repair of damaged DNA. That mechanism represents a novel approach that differs from traditional antibiotic and antiviral therapies. Invirsa is initially developing INV-102 as a primary treatment for acute keratoconjunctivitis (viral "pinkeye") and upper respiratory tract infections, both of which affect millions of Americans annually. INV-102 has demonstrated efficacy in animal models of acute adenoviral keratoconjunctivitis via topical application (eyedrops), and the company plans to advance the program into clinical development. The company recently closed $520,000 in seed financing to fund the next stages of development.

Total raised

$8M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2023